


JCO3 Rec'd PCT/PTO 25 APR 2005 PCT #3



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Scharer, et al.

Examiner: Unassigned

Application No.: 10/521,421

Group Art Unit: Unassigned

Filed: January 14, 2005

Docket: 753-45 PCT/US

For: PROCESS FOR INTRODUCING
A 1,2-DOUBLE BOND IN 3-
OXO-4-AZASTEROID
COMPOUNDS

Dated: April 21, 2004

I hereby certify this correspondence is being deposited with the
United States Postal Service as first class mail, postpaid in an envelope,
addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA
22313-1450
on April 21, 2004

Signature K.J. Goodhand/

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In fulfillment of the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicant submits herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98. It is understood that the information provided herein is solely for the purpose of fulfilling Applicant's obligations under the law and should not be construed as nor is it intended to be an admission of prior art.


Copies of the U.S. Patents and U.S. Patent Application Publications listed on the attached Form PTO-1449 are not provided as the U.S. Patent office have waived the requirement for paper submission of such documents. All foreign patents are listed on the Form 1449 and are enclosed.

Since this Information Disclosure Statement is being submitted before the issuance of a first Office Action, no fee is believed to be necessary. If, however, a fee is necessary, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-2461.

Accordingly, in view of the present submission, it is now believed that the present application is in all respects complete, and in condition for examination and favorable consideration.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicant's attorney at the telephone number set forth below.

Respectfully submitted,



John X. Haberman
Registration No.: 55,236
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 753-45 PCT/US	APPLICATION NO. 10/521,421
	APPLICANT Scharer et al.	CONFIRMATION NO. Unassigned
	FILING DATE 01/14/05	GROUP Unassigned

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		5,710,342	01/20/98	Imre et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		EP 0298652 A2	1/11/89	EPO				
		EP 0428366 A2	5/22/91	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Rasmusson G.H., et al.: "AZASTERIODS; STRUCTURE-ACTIVITY RELATIONSHIPS FOR INHIBITION OF 5ALPHA-REDUCTASE AND OF ANDROGEN RECEPTOR BINDING" Journal of Medicinal Chemistry, American Chemical Society, Washington, DC, U.S., vol. 29, no. 11, 1 November 1986 (1986-11-01), pages 2298-2315, XP000568779.
		Bhattacharya, Apurba, et al.: "SILYLATION-MEDIATED OXIDATION OF 4-AZA-3-KETOSTEROIDS WITH DDQ PROCEEDS VIA DDQ-SUBSTRATE ADDUCTS" Journal of the American Chemical Society, American Chemical Society, Washington, DC, U.S., vol. 110, 1988 pages 3318-3319, XP002179347.
		J. Tsuji, et al.: "PALLADIUM CATALYZED PREPARATION OF alpha.-ALLYL ESTERS AND alpha, beta-UNSATURATED ESTERS FROM SATURATED ESTERS VIA THEIR KETENE SILYL ACETALS" TETRAHEDRON LETTERS., vol. 25, no. 42, 1984, pages 4783-4786, XP002226639.
		International Application No. PCT/CH03/00435 - International Search Report.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.